CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 2017
About InfinityInfinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1 study in patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Contact:Jaren Irene Madden, Senior Director, Investor Relations and Corporate Communications617-453-1336 or [email protected]
View original content:http://www.prnewswire.com/news-releases/infinity-to-present-at-the-2017-bio-investor-forum-300532737.html
SOURCE Infinity Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All